{"id":"W3027850675","doi":"10.1016/j.cllc.2020.05.015","title":"Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report","year":2020,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Takeda Canada; Genentech; Meso Scale Diagnostics; Clovis Oncology; Chugai Pharmaceutical; Roche; Novartis; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AstraZeneca France; Takeda Pharmaceutical Company","keywords":"Crizotinib; Osimertinib; Medicine; Epidermal growth factor receptor; Lung cancer; Adenocarcinoma; Cancer research; Gefitinib; Tyrosine kinase; Oncology; Acquired resistance; Internal medicine; Erlotinib; Receptor; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009982736,0.0006523022,0.001016558,0.0002912823,0.0002772805,0.0009766332,0.0005265767,0.001156375,0.001321854],"category_scores_gemma":[0.000832041,0.0002204796,0.00118517,0.0004765963,0.0002766729,0.0006046757,0.0003483553,0.00225192,0.000510334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006697698,"about_ca_system_score_gemma":0.0007088353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004746416,"about_ca_topic_score_gemma":0.001988328,"domain_scores_codex":[0.9996859,0.00008362123,0.00005416951,0.00004042294,0.00005632899,0.00007945525],"domain_scores_gemma":[0.9997789,0.00009970251,0.00002902538,0.00001520545,0.00002790508,0.00004917712],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"case_report","study_design_scores_codex":[0.007066343,0.001551399,0.005627556,0.004061157,0.0009200384,0.01498336,0.0002666192,0.001022584,0.04827547,0.002802572,0.03797369,0.8754493],"study_design_scores_gemma":[0.003906874,0.0423746,0.04109009,0.001200805,0.004385658,0.07498557,0.0003731579,0.001962852,0.06696375,0.001962071,0.7606192,0.0001753367],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1319576,0.8217234,0.003629856,0.01354498,0.003206135,0.0006440803,0.0005464602,0.0001523571,0.02459508],"genre_scores_gemma":[0.4357072,0.5207749,0.005064454,0.01382233,0.008543932,0.0004770515,0.00183366,0.00006984132,0.01370671],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.001321854,"threshold_uncertainty_score":0.005279422,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05111740777455702,"score_gpt":0.4146171040608322,"score_spread":0.3634996962862752,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}